8 hours ago
China's Xiaomi unveils its first EV to rival Porsche, Tesla
Chinese consumer electronics giant Xiaomi unveiled its long-awaited electric car on Thursday, 28th, 2023, but declined to share its price or specific launch date.
CNBC | Evelyn Cheng
Chinese consumer electronics giant Xiaomi said Thursday it has spent 10 billion yuan ($1.4 billion) to enter the country's overcrowded electric-vehicle market and compete with the likes of Tesla and Porsche.
The model, called the Xiaomi SU7, is “in trial production and will hit the domestic market in a few months,” according to CEO Lei Jun. Tuesday's post X is a social media platform, formerly known as Twitter. “The price has not been finalized yet.”
The Xiaomi SU7, pronounced “Sue Qi” in Mandarin, beats Porsche's Taycan and Tesla's Model S in acceleration and other metrics, Lei said during Thursday's three-hour presentation.
Read the full story here.
– Evelyn Cheng
8 hours ago
CNBC Pro: Fund managers are wary of European stocks, BofA survey shows — here's why
Fund managers have struck a cautious tone about the prospects for the European economy – and the stock market – heading into 2024, but investors see some opportunities.
A recent survey by Bank of America showed that 68% of professional investors see upside in European stocks in 2024. BofA has 254 participants with a total of $691 billion in assets under management.
It comes after a flat year for European stocks that saw the Stoxx 600 index rise 12.65% as of December 28.
CNBC Pro subscribers can read about the expectations of fund managers here.
– Amala Balakrishna
8 hours ago
CNBC Pro: Piper Chandler Reveals Its Top 3 Biotech Picks for 2024 — And One Is Up 90%
Piper Sandler has named three small- and mid-cap pharma stocks as its “Top Picks” for 2024, thanks to their attractive valuations, product approvals/launch pipeline, innovation plans and clinical data readings for the coming year.
Investment bank confidence in biotech stocks is growing as the sector finally shows signs of recovery.
“After another tough year, there are signs that biotech will rebound in 2024. A pause or reversal in interest rate hikes is constructive for biotech funds and M&A (mergers and acquisitions) is active,” analysts at Piper Sandler said. Shares.
Subscribers
– Amala Balakrishna
